Comprehensive research information for laboratory professionals
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide engineered as a balanced triple agonist of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It represents the next generation of incretin-based research compounds, adding glucagon receptor activation to the dual agonism architecture seen in earlier molecules . Researchers study retatrutide in models of energy expenditure, hepatic glucose output, and metabolic regulation. Its unique molecular engineering allows it to maintain a continuous helical structure that threads through receptor transmembrane domains, enabling simultaneous multi-receptor engagement.